Monoclonal Anti-RSV-F0 broadly Antibody, Human IgG1 (3B4)

Catalog # RSV-M649

Source

Monoclonal Anti-RSV-F0 broadly Antibody, Human IgG1 (3B4) is a chimeric monoclonal antibody recombinantly expressed from human 293 cells (HEK293), which combines the variable region of a mouse monoclonal antibody with human IgG1 constant domain. The mouse monoclonal antibody is produced from a hybridoma resulting from fusion of SP2/0 myeloma and B-lymphocytes obtained from a mouse immunized with RSV-F0.

Isotype

Human IgG1 | Human Kappa

Specificity

This product is a specific antibody specifically reacts with RSV-F0.

Application

ELISA

Purity

>90% as determined by SDS-PAGE.

Endotoxin

Less than 1.0 EU per μg by the LAL method.

Formulation

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

Reconstitution

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage


For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:


- -20°C to -70°C for 12 months in lyophilized state;
- -70 °C for 3 months after reconstitution;

SDS-PAGE




Monoclonal Anti-RSV-F0 broadly Antibody, Human IgG1 (3B4) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).


Bioactivity-Elisa




Immobilized HRSV (A) Post-fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H6) at 1 μg/mL (100 μL/well) can bind Monoclonal Anti-RSV-F0 broadly Antibody, Human IgG1 (3B4) (Cat. No. RSV-M649) with a linear range of 0.1-4 ng/mL (QC tested).



Immobilized HRSV (A) Pre-fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H7) at 1 μg/mL (100 μL/well) can bind Monoclonal Anti-RSV-F0 broadly Antibody, Human IgG1 (3B4) (Cat. No. RSV-M649) with a linear range of 0.1-2 ng/mL (QC tested).



Immobilized HRSV (B) Pre-fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H8) at 1 μg/mL (100 μL/well) can bind Monoclonal Anti-RSV-F0 broadly Antibody, Human IgG1 (3B4) (Cat. No. RSV-M649) with a linear range of 0.1-0.5 ng/mL (Routinely tested).



Immobilized HRSV (B) Post-fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H9) at 1 μg/mL (100 μL/well) can bind Monoclonal Anti-RSV-F0 broadly Antibody, Human IgG1 (3B4) (Cat. No. RSV-M649) with a linear range of 0.1-1 ng/mL (Routinely tested).

Background

Human respiratory syncytial virus (HRSV) is the most common etiological agent of acute lower respiratory tract disease in infants and can cause repeated infections throughout life. The RSV fusion glycoprotein (RSV F) is the principal target of RSV neutralizing antibodies in human sera. The RSV F is a type I viral fusion protein synthesized as inactive, single-chain polypeptides that assemble into trimers. RSV F fuses the viral and host cell membranes by irreversible protein refolding from the labile prefusion conformation to the stable post-fusion conformation.

Clinical and Translational Updates

Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.